A compound of Formula II: or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof, wherein: A is CONHOH; B is CH 2; G is CH 2; X is CH 2 NR b; Y is CH 2; M is CO; U is absent; V is azetidin-1-yl, 2,5-dihydro-1H-pyrrol-1-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, isoquinol-2-yl, pyridin-1-yl, 3,6-dihydropyridin-1-yl, 2,3-dihydroindol-1-yl, 1,3,4,9-tetrahydrocarbolin-2-yl, thieno[2,3-c]pyridin-6-yl, 3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl, 1,2,4,4a,5,6-hexahydro-pyrazino[1,2-a]quinolin-3-yl, pyrazino[1,2-a]quinolin-3-yl, diazepan-1-yl, 1,4,5,6-tetrahydro-2H-benzo[f]isoquinolin-3-yl, 1,4,4a,5,6,10b-hexahydro-2H-benzo[f]isoquinolin-3-yl, 3,3a,8,8a-tetrahydro-1H-2-aza-cyclopenta[a]inden-2-yl, or 2,3,4,7-tetrahydro-1H-azepin-1-yl, azepan-1-yl;; U' is absent; V' is C 3-13 carbocyclyl substituted with 0-5 R e; each R e is, independently, H, T, C 1-8 alkylene-T, C 2-8 alkenylene-T, C 2-6 alkynylene-T, C NR a '(CR b 'R c ') r -T, C O(CR b 'R c ') r -T, S p (CR b 'R c ') r -T, (CR b 'R c ') r -O-(CR b 'R c ') r -T, OH, Cl, F, Br, I, CN, NO 2, NR I R II, COR III, COOR IV, OR IV, CONR I R II, NR I CONR I R II, OCONR I R II, NR I COR II, SO 2 NR I R II, NR I SO 2 R II, NR I SO 2 NR I R II, OSO 2 NR I R II, SO p R V, C 1-8 haloalkyl, C 3-13 carbocyclyl, heterocyclyl, carbocyclylalkyl, or heterocyclylalkyl, wherein each of said carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocylcylalkyl groups is optionally substituted by one or more C 1-8 alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, carboxy alkyl ester, carboxy aryl ester, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, sulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylsulfinyl, alkylsulfonyl or arylsufonyl; R b is H, C O(CR b 'R c ') r - T or C (CR b 'R c ') r -T; each T is independently H, C 1-10 alkyl; C 2-10 alkynyl, or heterocyclyl; R a ' is H or C 1-6 alkyl; R b ' and R c ' are both H; R 1 is hydrogen; R 2 is hydrogen; R 4 ' is H; R 5 ' is H; R I and R II are each, independently, H, C 1-6 alkyl or C 3-13 carbocyclyl; R III and R IV are each, independently, H, C 1-6 alkyl, haloalkyl, carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl, wherein said carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl are each optionally substituted by one or more halo, C 1-4 alkyl or C 1-4 alkoxy; R V is C 1-6 alkyl, haloalkyl, carbocyclyl or heterocyclyl; p = 1 or 2; and r = 0, 1 or 2; wherein, except where otherwise indicated, each aryl is C 6-20 aryl; each alkyl is C 1-20 alkyl; each carbocyclyl is C 3-30 carbocyclyl; and each heterocyclyl is a saturated or unsaturated carbocyclic group containing 3 to 14 ring-forming atoms wherein at least one ring-forming carbon atom is replaced by a heteroatom selected from O, S and N; with the proviso that NR b has no N-N or N-O bonds. A is CONHOH; B is CH 2; G is CH 2; X is CH 2 NR b; Y is CH 2; M is CO; U is absent; V is azetidin-1-yl, 2,5-dihydro-1H-pyrrol-1-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, isoquinol-2-yl, pyridin-1-yl, 3,6-dihydropyridin-1-yl, 2,3-dihydroindol-1-yl, 1,3,4,9-tetrahydrocarbolin-2-yl, thieno[2,3-c]pyridin-6-yl, 3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl, 1,2,4,4a,5,6-hexahydro-pyrazino[1,2-a]quinolin-3-yl, pyrazino[1,2-a]quinolin-3-yl, diazepan-1-yl, 1,4,5,6-tetrahydro-2H-benzo[f]isoquinolin-3-yl, 1,4,4a,5,6,10b-hexahydro-2H-benzo[f]isoquinolin-3-yl, 3,3a,8,8a-tetrahydro-1H-2-aza-cyclopenta[a]inden-2-yl, or 2,3,4,7-tetrahydro-1H-azepin-1-yl, azepan-1-yl;; U' is absent; V' is C 3-13 carbocyclyl substituted with 0-5 R e; each R e is, independently, H, T, C 1-8 alkylene-T, C 2-8 alkenylene-T, C 2-6 alkynylene-T, C NR a '(CR b 'R c ') r -T, C O(CR b 'R c ') r -T, S p (CR b 'R c ') r -T, (CR b 'R c ') r -O-(CR b 'R c ') r -T, OH, Cl, F, Br, I, CN, NO 2, NR I R II, COR III, COOR IV, OR IV, CONR I R II, NR I CONR I R II, OCONR I R II, NR I COR II, SO 2 NR I R II, NR I SO 2 R II, NR I SO 2 NR I R II, OSO 2 NR I R II, SO p R V, C 1-8 haloalkyl, C 3-13 carbocyclyl, heterocyclyl, carbocyclylalkyl, or heterocyclylalkyl, wherein each of said carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocylcylalkyl groups is optionally substituted by one or more C 1-8 alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, carboxy alkyl ester, carboxy aryl ester, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, sulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylsulfinyl, alkylsulfonyl or arylsufonyl; R b is H, C O(CR b 'R c ') r - T or C (CR b 'R c ') r -T; each T is independently H, C 1-10 alkyl; C 2-10 alkynyl, or heterocyclyl; R a ' is H or C 1-6 alkyl; R b ' and R c ' are both H; R 1 is hydrogen; R 2 is hydrogen; R 4 ' is H; R 5 ' is H; R I and R II are each, independently, H, C 1-6 alkyl or C 3-13 carbocyclyl; R III and R IV are each, independently, H, C 1-6 alkyl, haloalkyl, carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl, wherein said carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl are each optionally substituted by one or more halo, C 1-4 alkyl or C 1-4 alkoxy; R V is C 1-6 alkyl, haloalkyl, carbocyclyl or heterocyclyl; p = 1 or 2; and r = 0, 1 or 2; wherein, except where otherwise indicated, each aryl is C 6-20 aryl; each alkyl is C 1-20 alkyl; each carbocyclyl is C 3-30 carbocyclyl; and each heterocyclyl is a saturated or unsaturated carbocyclic group containing 3 to 14 ring-forming atoms wherein at least one ring-forming carbon atom is replaced by a heteroatom selected from O, S and N; with the proviso that NR b has no N-N or N-O bonds.